Sinovac could further boost Pharmaniaga sales in 1H22

KUALA LUMPUR: Further earnings growth for Pharmaniaga Bhd could come from the Sinovac vaccines' potential to be approved as a booster shot and for adolescent use, says Kenanga Research, although this would likely be only rolled-out in 1H22.

The research firm noted that after recording bumper profits in 3QFY21, there could be no sequential earnings growth for Pharmaniaga in the final quarter of this year, as any requirement for a Sinovac vaccine booster shot would potentially start from December onwards.